相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer
Ghaneya Al-Khadairi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer
Caroline Kreuzinger et al.
CANCER LETTERS (2019)
Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma
Amy C. Schefler et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2019)
The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma
Bin Xu et al.
HISTOPATHOLOGY (2019)
Super-enhancers: critical roles and therapeutic targets in hematologic malignancies
Yunlu Jia et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
Breelyn A. Wilky et al.
LANCET ONCOLOGY (2019)
Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics
Kathleen A. Cronin et al.
CANCER (2018)
Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway
Hanzhang Zhu et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Combined analysis of DNA methylation and gene expression profiles of osteosarcoma identified several prognosis signatures
Wen Tian et al.
GENE (2018)
SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Acticates CD4+ T Lymphocytes
Markus D. Lacher et al.
FRONTIERS IN IMMUNOLOGY (2018)
Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma
Louis Cai et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2018)
Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?
Anna Tessari et al.
BREAST (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non-small cell lung cancer patients
Szu-Hua Pan et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
PRAME overexpression predicted good outcome in pediatric B-cell acute lymphoblastic leukemia patients receiving chemotherapy
Yan-Huan Zhang et al.
LEUKEMIA RESEARCH (2017)
Soft tissue sarcomas: From a morphological to a molecular biological approach
Yoshinao Oda et al.
PATHOLOGY INTERNATIONAL (2017)
PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma
Gulcin Gezgin et al.
JAMA OPHTHALMOLOGY (2017)
Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy
Yoshihiro Oka et al.
ONCOLOGY RESEARCH AND TREATMENT (2017)
PRAME Gene Copy Number Variation Is Related to Its Expression in Multiple Myeloma
Lu Yang et al.
DNA AND CELL BIOLOGY (2017)
Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells
Yong-Kyu Lee et al.
CANCER LETTERS (2017)
Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes
Jason Roszik et al.
CLINICAL SARCOMA RESEARCH (2017)
Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation
Xiao-Dong Mo et al.
ANNALS OF HEMATOLOGY (2016)
The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas
Daniel Nettersheim et al.
BRITISH JOURNAL OF CANCER (2016)
PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma
Matthew G. Field et al.
CLINICAL CANCER RESEARCH (2016)
PRAME is critical for breast cancer growth and metastasis abs
Zhengwang Sun et al.
GENE (2016)
A transcriptional target of androgen receptor, miR-421 regulates proliferation and metabolism of prostate cancer cells
Delong Meng et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2016)
Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study
Jean-Louis Pujol et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients
Sumitra Thongprasert et al.
LUNG CANCER (2016)
Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas
Matthew G. Field et al.
ONCOTARGET (2016)
PRAME expression and promoter hypomethylation in epithelial ovarian cancer
Wa Zhang et al.
ONCOTARGET (2016)
Preferentially Expressed Antigen of Melanoma Prevents Lung Cancer Metastasis
Quan Huang et al.
PLOS ONE (2016)
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study
R. Gutzmer et al.
ESMO OPEN (2016)
PRAME Expression and Its Clinical Relevance in Hodgkin's Lymphoma
Vehbi Ercolak et al.
ACTA HAEMATOLOGICA (2015)
Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma
Kunio Iura et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2015)
Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals
Bianca Altvater et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Prognostic significance of PRAME expression based on immunohistochemistry for diffuse large B-cell lymphoma patients treated with R-CHOP therapy
Kenjiro Mitsuhashi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma
Jessica A. Hemminger et al.
MODERN PATHOLOGY (2014)
Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy
Anna Babiak et al.
ONCOLOGY REPORTS (2014)
High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation
Fabio G. Liberante et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Gene Expression Profiling using Nanostring Digital RNA Counting to Identify Potential Target Antigens for Melanoma Immunotherapy
Rachel E. Beard et al.
CLINICAL CANCER RESEARCH (2013)
PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes
Ya-Zhen Qin et al.
LEUKEMIA & LYMPHOMA (2013)
PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions
Miroslaw J. Szczepanski et al.
ORAL ONCOLOGY (2013)
Expression and prognostic relevance of PRAME in primary osteosarcoma
Pingxian Tan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
The cancer testis antigen PRAME as a biomarker for solid tumor cancer management
Steve Goodison et al.
BIOMARKERS IN MEDICINE (2012)
Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma
L. Dyrskjot et al.
BRITISH JOURNAL OF CANCER (2012)
Hodgkin's lymphoma RNA-transfected dendritic cells induce cancer/testis antigen-specific immune responses
Carolin Winkler et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Vaccines in non-small cell lung cancer: Rationale, combination strategies and update on clinical trials
Tommaso De Pas et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
NYESO-1/LAGE-1s and PRAME Are Targets for Antigen Specific T Cells in Chondrosarcoma following Treatment with 5-Aza-2-Deoxycitabine
Seth M. Pollack et al.
PLOS ONE (2012)
Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia
Djordje Atanackovic et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells
Concetta Quintarelli et al.
BLOOD (2011)
A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors
Jeffrey S. Weber et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells
Norina Tanaka et al.
LEUKEMIA RESEARCH (2011)
BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients
D. D. De Carvalho et al.
ONCOGENE (2011)
Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells
Marie Bleakley et al.
BLOOD (2010)
Derivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approach
Yijun Sun et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Efficacious Immune Therapy in Chronic Myelogenous Leukemia (CML) Recognizes Antigens That Are Expressed on CML Progenitor Cells
Melinda A. Biernacki et al.
CANCER RESEARCH (2010)
Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia
Frances Wadelin et al.
MOLECULAR CANCER (2010)
Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia
Tim Luetkens et al.
LEUKEMIA RESEARCH (2010)
Identification of genes associated with non-small-cell lung cancer promotion and progression
Jasna Bankovic et al.
LUNG CANCER (2010)
Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia
Katayoun Rezvani et al.
BLOOD (2009)
Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia
Carlos M. Santamaria et al.
BLOOD (2009)
External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomast
Karolina Partheen et al.
BMC CANCER (2009)
Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia
Christina A. Ortmann et al.
ANNALS OF HEMATOLOGY (2008)
Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia
Concetta Quintarelli et al.
BLOOD (2008)
PRAME expression and clinical outcome of breast cancer
M. T. Epping et al.
BRITISH JOURNAL OF CANCER (2008)
Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs
Martin S. Staege et al.
EXPERIMENTAL HEMATOLOGY (2008)
The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia
Carlos Santamaria et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas
Karolina Partheen et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Prevalence and prognostic and predictive relevance of PRAME in breast cancer
Padraig Doolan et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors
Mirjam T. Epping et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Epigenetic regulation of PRAME gene in chronic myeloid leukemia
Ose Roman-Gomez et al.
LEUKEMIA RESEARCH (2007)
Hypomethylation of PRAMS is responsible for its aberrant overexpression in human malignancies
Tino Schenk et al.
GENES CHROMOSOMES & CANCER (2007)
Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia
A. Spanaki et al.
LEUKEMIA RESEARCH (2007)
Improved breast cancer prognosis through the combination of clinical and genetic markers
Yijun Sun et al.
BIOINFORMATICS (2007)
Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches
Jochen Greiner et al.
BLOOD (2006)
Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors
Karolina Partheen et al.
EUROPEAN JOURNAL OF CANCER (2006)
Identification of HLA class I-restricted tumor-associated antigens in adult T cell leukemia cells by mass spectrometric analysis
Masahiro Kawahara et al.
EXPERIMENTAL HEMATOLOGY (2006)
Expression of cancer testis antigens in head and neck squamous cell carcinomas
David L. A. Figueiredo et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2006)
Detection and functional analysis of CD8+ T cells specific for PRAME:: a target for T-cell therapy
Marieke Griffioen et al.
CLINICAL CANCER RESEARCH (2006)
Gene expression changes associated with progression and response in chronic myeloid leukemia
JP Radich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The human tumor antigen repressor of retinoic acid PRAME is a dominant receptor signaling
MT Epping et al.
CELL (2005)
Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo
N Tajeddine et al.
CANCER RESEARCH (2005)
Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens
L Li et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies
J Greiner et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Predicting biomarkers for ovarian cancer using gene-expression microarrays
TR Adib et al.
BRITISH JOURNAL OF CANCER (2004)
Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2′-deoxycytidine
L Sigalotti et al.
CANCER RESEARCH (2004)
The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome
A Oberthuer et al.
CLINICAL CANCER RESEARCH (2004)
Gene expression patterns that characterize advanced stage serous ovarian cancers
JM Lancaster et al.
JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION (2004)
Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker
S McElwaine et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Gene expression profiling predicts clinical outcome of breast cancer
LJ van't Veer et al.
NATURE (2002)
Clinical implications of PRAME gene expression in childhood acute myeloid leukemia
D Steinbach et al.
CANCER GENETICS AND CYTOGENETICS (2002)
Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia
M Matsushita et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
分享论文
